Likang to Present AI Cancer Immunotherapy Platform in Abu Dhabi
Likang Life Sciences will present its personalized cancer immunotherapy platform at the Abu Dhabi Future Health Summit 2026, the company said in a press release. The event will run from October 20 to 22 at the ADNEC Centre in Abu Dhabi.
Likang uses AI to identify and prioritize tumor neoantigens specific to individual patients. Its pipeline includes personalized cancer vaccines and T cell therapies targeting those neoantigens.
The company will also present its lead candidate, LK101, a personalized neoantigen mRNA DC cancer vaccine. LK101 received clinical trial authorization in China in 2023 and Investigational New Drug clearance from the US Food and Drug Administration in 2025. Likang cofounder and vice chairman Shannon Cheung will join an October 21 panel on precision oncology and cancer treatment.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 14 Taiwanese Health Technology Groups Test US Market in Dallas Oct 14 INmune Bio and QCi Apply Quantum Computing to XPro Research Oct 14 WeInfuse and Clarion Connect AI Agents to Infusion Workflows Oct 14 Brainomix and Pulmonary Fibrosis Foundation Partner on AI Lung Imaging Research Oct 14 Illumina Launches BioInsight Platform for Genomic ResearchLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
LUNGevity Awards $2 Million for Lung Nodule Risk Studies
Linearis Joins Two Canadian AI Health Data Projects
OpenAI Foundation Gives UNC Lineberger $40 Million for Cancer Vaccine Research
MediSights Reports Study Using AI Agents for Myeloma Market Research
AbbVie Partners With Valkai on AI Tools for Clinical Development
Daily AI Brief: the AI news that matters, in your inbox.